A double blind placebo controlled trial investigating the efficacy of Clopidogrel as prophylactic treatment for migrane. - Clopidogrel as prophylactic treatment for migrane
- Conditions
- MigraineMedDRA version: 9.1Level: LLTClassification code 10027599Term: Migraine
- Registration Number
- EUCTR2008-001604-23-GB
- Lead Sponsor
- Guy's & St Thomas' NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 286
Participants aged > 18
Definite migraine with or without aura as defined by International Headache criteria
Headache or aura occurring on 4 or more days and less than 15 days in a 28 day month
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
High risk features suggesting cerebral malignancy,
More than 15 headache days each month
Contraindications to clopidogrel therapy (hypersensitivity, active bleeding, warfarin therapy, hepatic dysfunction)
Already prescribed clopidogrel (recent acute coronary syndrome, TIA with aspirin hypersensitivity)
Requirement for routine nonsteroidal anti-inflammatory agents (occaisional use is allowed)
Use of an investigational product within the previous 3 months
Clinically significant abnormal platelet or liver function at visit 1
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method